Breaking Down Nexus AG Financial Health: Key Insights for Investors

Curious whether Nexus AG is a resilient growth story or an overvalued healthcare‑IT name? In Q2 (ending June 30, 2025) the company posted revenue of €71.75 million (up 9.10% from the prior quarter) and TTM revenue of €278.55 million (YoY +6.57%), with a market cap of €1.08 billion and a stock price at €71.50 (Nov 4, 2025); profitability shows net income (TTM) of €29.64 million and EPS €1.72, an operating margin of 14.08% and profit margin 12.28%, while returns (ROE 12.28%, ROA 5.44%, ROIC 8.17%) sit alongside conservative leverage - debt/equity 0.07 and a net cash position of €106.41 million backed by €123.54 million in cash - supporting strong liquidity (current ratio 2.11, quick ratio 1.99) and free cash flow of €44.16 million; valuation metrics (P/E 36.97, EV €977.84 million, EV/EBITDA 20.04, P/S 4.53, P/B 4.25) raise questions about investor expectations amid low bankruptcy risk (Altman Z‑Score 5.29) and operating strengths, while sector competition, regional concentration, regulation, currency swings and cyber threats highlight material risks-read on for a deep dive into revenue drivers, margin sustainability, balance‑sheet resilience and the growth levers that could justify (or challenge) the current valuation

Nexus AG (0FGL.L) Revenue Analysis

In the quarter ending June 30, 2025, Nexus AG reported revenue of €71.75 million, a 9.10% increase from the prior quarter. Trailing twelve months (TTM) revenue is €278.55 million, reflecting 6.57% year-over-year growth. For full-year 2024 the company recorded €265.52 million in revenue, up 8.27% from €245.24 million in 2023.

• Quarter (Q2 2025): €71.75M - +9.10% vs prior quarter
• TTM: €278.55M - +6.57% YoY
• FY 2024: €265.52M - +8.27% vs FY 2023 (€245.24M)

Key revenue drivers and considerations:

• Quarterly momentum: 9.10% sequential increase suggests improving sales cycles or seasonality benefits.
• Moderate YoY growth: 6.57% TTM growth indicates steady expansion but requires monitoring against peers.
• Workforce efficiency: €145,910 revenue per employee implies operational scale - useful for benchmarking.
• Valuation context: P/S of 4.53 and €1.08B market cap reflect market expectations for growth and profitability conversion.

For more context on corporate strategy, ownership and how Nexus AG operates, see: Nexus AG: History, Ownership, Mission, How It Works & Makes Money

Nexus AG (0FGL.L) - Profitability Metrics

Nexus AG (0FGL.L) presents a clear profitability profile for the trailing twelve months, showing solid margins and returns that help frame investor expectations around earnings quality and capital efficiency.

• Net income (TTM): €29.64 million - EPS: €1.72
• Operating income: €33.62 million - Operating margin: 14.08%
• Profit margin: 12.28%
• Return on equity (ROE): 12.28%
• Return on assets (ROA): 5.44%
• Return on invested capital (ROIC): 8.17%

Key takeaways for investors focus on a stable net income and double-digit margins that align ROE with profit margin, while ROA and ROIC indicate room for improved asset and capital deployment to lift overall returns. For broader context on corporate direction, see Mission Statement, Vision, & Core Values (2026) of Nexus AG.

Nexus AG (0FGL.L) - Debt vs. Equity Structure

• Debt-to-Equity Ratio: 0.07 - very low leverage versus shareholders' equity.
• Cash & Cash Equivalents: €123.54 million - substantial liquid resources on the balance sheet.
• Total Debt: €17.13 million - limited absolute debt exposure.
• Net Cash Position: €106.41 million (Cash - Debt).
• Interest Coverage Ratio: 19.24 - EBITDA covers interest expense nearly 19.24 times.
• Debt-to-EBITDA: 0.36 - less than half a year of EBITDA would cover outstanding debt.
• Debt-to-Free Cash Flow: 0.39 - debt equal to roughly 0.39 years of free cash flow, indicating efficient cash generation.

• Flexibility for M&A or capital returns due to net cash and low fixed financing obligations.
• Lower financial distress risk in downturns given the 19.24 interest coverage and ample cash reserves.
• Capacity to increase leverage selectively if pursuing higher-return investments while maintaining conservative ratios.

Nexus AG (0FGL.L) - Liquidity and Solvency

Nexus AG presents a strong short-term liquidity profile and low solvency risk based on most recent reported figures.

• Current ratio: 2.11 - sufficient short-term assets to cover liabilities.
• Quick ratio: 1.99 - strong immediate liquidity excluding inventories.
• Operating cash flow: €52.31 million.
• Capital expenditures (CapEx): €8.15 million.
• Free cash flow (FCF): €44.16 million (OCF - CapEx).
• Altman Z-Score: 5.29 - indicates low bankruptcy risk.
• Piotroski F-Score: 6 - suggests solid financial health.
• Effective tax rate: 24.66%.

Key liquidity drivers include high operating cash conversion and modest CapEx, translating into robust free cash flow that supports debt servicing and strategic flexibility.

For broader context on the company's background and business model, see: Nexus AG: History, Ownership, Mission, How It Works & Makes Money

Nexus AG (0FGL.L) Valuation Analysis

• Trailing P/E: 36.97 - market paying €36.97 for each €1 of trailing earnings.
• Enterprise Value (EV): €977.84 million - aggregate market value of equity and net debt.
• EV/EBITDA: 20.04 - elevated relative to typical mid-market industrial peers, implying high expectations for recurring operating performance.
• EV/Sales: 3.98 - nearly 4x revenue valuation, signaling a premium on revenue quality or growth prospects.
• EV/Free Cash Flow: 22.14 - investors value each euro of free cash flow at ~€22.14, indicating focus on cash conversion but with stretched valuation.
• Price/Book (P/B): 4.25 - equity valued over four times book value.
• Price/Tangible Book (P/TBV): 16.04 - very high valuation relative to tangible net assets, suggesting intangible value or expected returns far above asset replacement.

Nexus AG (0FGL.L) - Risk Factors

• Competitive pressure from global EHR vendors: Nexus AG competes against established multinational providers with larger R&D budgets and global sales channels. Market-share erosion in adjacent segments could compress pricing and margins.
• Regional concentration: Approximately 68% of revenue is generated in the German-speaking market (DACH), increasing sensitivity to local economic cycles, reimbursement changes and hospital/clinic ICT spending patterns.
• Technology obsolescence: The product lifecycle in healthcare IT requires continuous investment. Nexus's R&D intensity (R&D spend ~8.2% of revenue in FY2023) must be maintained to avoid obsolescence.
• Currency exposure: With ~22% of revenue outside EUR and portions invoiced in CHF and GBP, FX moves can swing reported revenue and EBIT. Management reports an estimated ±1% FX movement could change reported EBIT by ~€0.6-1.2m.
• Regulatory adaptation costs: Changes to interoperability standards, data portability rules or medical device regulations can necessitate substantial rework and certification costs, impacting near‑term margins.
• Cybersecurity threats: As a custodian of clinical and administrative data, breaches could trigger remediation costs, regulatory fines and loss of client trust. Historically, Nexus reported zero major breaches in the last three years, but incident risk remains material.

• Key operational levers for risk mitigation:
  • Diversify geographic revenue mix to lower DACH concentration over a 3-5 year horizon.
  • Maintain R&D at or above current levels (8%-10% of revenue) to stay competitive on EHR interoperability and cloud offerings.
  • Implement active FX hedging for material non‑EUR exposures to stabilize reported results.
  • Ensure continuous security audits and invest in SOC/incident response to limit breach impact.

Nexus AG (0FGL.L) Growth Opportunities

• Digitization of healthcare records and workflows can expand demand for cloud-native EHR, interoperability and telehealth modules.
• Cross-selling NEXUS/CLOUD IT and adjacent modules to existing customer bases can increase wallet share and recurring revenue.
• Geographic expansion into selected European and APAC markets offers low-hanging revenue upside where digital health regulation and funding are accelerating adoption.
• Targeted acquisitions (clinical software, data analytics, regional integrators) can accelerate time-to-market and broaden product portfolio.
• Increased R&D investment focused on AI-assisted clinical decision support and interoperability standards can create differentiated, premium-priced offerings.
• Strategic partnerships with large hospital groups, payers and systems integrators can provide scale, long-term contracts and reference sites.

• KPIs to monitor: ARR growth, gross margin on cloud services, customer retention (NRR), average contract value (ACV), payback period on new customer acquisition, R&D ROI and number of live integration partners.
• Pricing levers: shift to subscription/consumption models, outcome-linked pricing for large providers, premium pricing for AI-enabled modules.
• Operational levers: streamline implementation via standardized deployment templates, invest in professional services efficiency and establish regional delivery centers to reduce time-to-value.